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Platelet Reactivity and Risk of
Ischemic Stroke After Coronary
Drug-Eluting Stent Implantation
From the ADAPT-DES Study
Gennaro Giustino, MD,a,b,* Björn Redfors, MD, PHD,b,* Ajay J. Kirtane, MD, SM,b,c Roxana Mehran, MD,a,b
George D. Dangas, MD, PHD,a,b Bernhard Witzenbichler, MD,d Franz-Josef Neumann, MD,e Giora Weisz, MD,b,c,f
Philippe Généreux, MD,b,c,g Akiko Maehara, MD,b,c Thomas McAndrew, PHD,b Serdar Farhan, MD,a
Michael J. Rinaldi, MD,h D. Christopher Metzger, MD,i Timothy D. Henry, MD,j,k David A. Cox, MD,l
Peter L. Duffy, MD,m Ernest L. Mazzaferri, JR, MD,n Bruce R. Brodie, MD,o Thomas D. Stuckey, MD,o Paul Gurbel, MD,p
Ori Ben-Yehuda, MD,b,c Gregg W. Stone, MDb,c

ABSTRACT
OBJECTIVES The authors sought to investigate the association between P2Y12 reaction units (PRU) and the risk of
ischemic stroke (IS) after successful coronary drug-eluting stents (DES) implantation.
BACKGROUND The association between platelet reactivity on clopidogrel and the risk for ischemic cerebrovascular
events remains unclear.
METHODS Incidence, predictors, and prognostic impact of IS were evaluated among patients enrolled in the multicenter, prospective ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents) study. By protocol,
patients were maintained on aspirin for 2 years and clopidogrel for at least 1 year. Baseline platelet reactivity on clopidogrel and aspirin were assessed by means of VerifyNow point-of-care assay after successful DES implantation.
RESULTS Among 8,582 patients enrolled, 68 (0.8%) had an IS during 2-year follow-up. Across the spectrum of
PRU, rates of IS were progressively greater as patients transitioned from the lowest quintile of PRU (more
P2Y12 receptor inhibition; 2-year rate of 0.51%) to the highest quintile of PRU (less P2Y12 receptor inhibition; 2-year
rate of 1.34%; adjusted p ¼ 0.04). PRU >208 was independently associated with higher risk of IS at 2 years
(adjusted hazard ratio 1.81; 95% conﬁdence interval 1.08 to 3.04; p ¼ 0.03). The association between higher
PRU and risk for IS was also consistent in patients with versus without high CHA2DS2-VASc score (pinteraction ¼ 0.30)
and in those on or off oral anticoagulation at discharge (pinteraction ¼ 0.99). Occurrence of IS was strongly
associated with increased risk of all-cause mortality at 2 years (adjusted HR: 4.16; 95% CI: 1.95 to 8.87; p < 0.0001).
CONCLUSIONS Higher PRU was associated with increased risk of IS after coronary DES implantation. Ensuring
adequate platelet P2Y12 receptor inhibition may reduce the risk of IS in this patient population. (Assessment of Dual
AntiPlatelet Therapy With Drug Eluting Stents [ADAPT-DES]; NCT00638794) (J Am Coll Cardiol Intv 2018;11:1277–86)
© 2018 by the American College of Cardiology Foundation.
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ABBREVIATIONS
AND ACRONYMS
ARU = aspirin reaction unit(s)
CI = conﬁdence interval
DAPT = dual antiplatelet
therapy

A

fter percutaneous coronary intervention

(PCI)

with

Stroke is a devastating clinical event associated

drug-eluting

with substantial morbidity and mortality (7). Patients

stents (DES), a period of dual anti-

with coronary artery disease are also at an increased

platelet therapy (DAPT) combining a P2Y 12

risk of ischemic stroke (IS) due to concomitant

receptor inhibitor and aspirin is recommen-

atherosclerotic disease within the extra- and intra-

ded to prevent the occurrence of stent-

cranial arterial system or due to cardiogenic embo-

related thrombotic complications (1). The

lism (7–9). Whether the degree of residual P2Y12

pathobiological rationale of DAPT post-PCI

receptor inhibition inﬂuences the risk of IS in a PCI

is predicated on the need to protect the

population, in which the primary indication of DAPT

stented vascular segment while vascular

is the prevention of coronary-related events, remains

IS = ischemic stroke

healing and stent strut endothelialization

unclear. Therefore, in the largescale ADAPT-DES

PCI = percutaneous coronary

are ongoing (1,2). Additionally, platelet inhi-

(Assessment of Dual Antiplatelet Therapy with Drug-

bition may prevent the development of

Eluting Stents) study, we sought to investigate the

atherothrombosis arising from atheroscle-

association between platelet reactivity on clopidogrel

rosis progression and acute plaque changes

and aspirin and the risk of IS in patients with coronary

DES = drug-eluting stent(s)
HR = hazard ratio
HS = hemorrhagic stroke

intervention

PRU = P2Y12 reaction unit(s)
ST = stent thrombosis

occurring outside the stented vascular segment,
within

the

coronary

vasculature,

and

artery disease who underwent successful DES-PCI.

possibly

SEE PAGE 1287

throughout the systemic arterial system (3,4). A signiﬁcant

interindividual

variability

in

platelet

METHODS

response to clopidogrel has been described and has
been attributed to genetic and epigenetic factors

STUDY DESIGN AND OBJECTIVES. The ADAPT-DES

that inﬂuence pharmacokinetic and pharmacody-

study was a prospective, multicenter registry specif-

namic properties of clopidogrel (5,6). As such, high

ically designed to determine the association between

on-clopidogrel platelet reactivity has been widely

platelet reactivity and ST after DES implantation. The

described as a strong independent predictor of

design and major outcomes of the ADAPT-DES study

increased risk of stent thrombosis (ST) and myocar-

have been previously described (6). In brief, a total of

dial infarction after PCI (5,6).

8,582 all-comers patients were prospectively enrolled
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at 11 sites in the United States and Germany.

F I G U R E 1 Rates of Stroke at 2 Years After PCI With DES

All patients who were successfully treated with 1 or
more DES and who were adequately loaded with
aspirin and clopidogrel were eligible for enrollment,
regardless of clinical presentation (51.7% had an acute
coronary syndrome) or procedural complexity. The
only major exclusion criteria were the occurrence of a
major complication during the procedure or before
platelet function testing, or if bypass surgery was
planned

after

PCI.

Additionally,

patients

with

hemoglobin <10 mg/dl and platelet count <100,000/
mm 3 were excluded from the study cohort. Platelet
reactivity on aspirin and clopidogrel was assessed after
an adequate loading period to ensure full antiplatelet
effect using the VerifyNow Aspirin, P2Y 12, and IIb/IIIa
assays (Accumetrics, San Diego, California) (6). After
PCI, patients were treated with aspirin indeﬁnitely,
and clopidogrel was recommended for at least 1 year.
All other treatments were as per standard of care.
Clinical follow-up was scheduled at 30 days, 1 year,

Kaplan-Meier curves for any stroke, ischemic stroke, and hemorrhagic stroke at 2-year
follow-up. DES ¼ drug-eluting stent(s); PCI ¼ percutaneous coronary intervention.

T A B L E 1 Baseline Clinical Characteristics in Patients With IS, HS, and No Stroke at 2-Year Follow-Up

Ischemic Stroke
(n ¼ 68)

Hemorrhagic Stroke
(n ¼ 14)

No Stroke
(n ¼ 8,500)

p Value*

p Value†

Age, yrs

67.1  10.0

69.1  11.1

63.6  10.9

0.006

0.04

Male

60.3 (41/68)

50.0 (7/14)

74.2 (6,309/8,500)

0.005

0.06

0.55

0.39

Race
Caucasian

91.2 (62/68)

100.0 (14/14)

88.6 (7,529/8,500)

8.8 (6/68)

0.0 (0/14)

11.4 (971/8,500)

30.2  5.6

26.9  4.3

29.5  5.7

0.36

0.07

Diabetes mellitus

47.1 (32/68)

28.6 (4/14)

32.3 (2,747/8,500)

0.02

1.00

Insulin-treated

44.1 (30/68)

28.6 (4/14)

28.2 (2,395/8,500)

0.005

1.00

25.0 (17/68)

7.1 (1/14)

10.1 (858/8,500)

<0.0001

1.00

Non-Caucasian
Body mass index, kg/m2

Peripheral artery disease
Congestive heart failure

14.7 (10/68)

7.1 (1/14)

8.1 (688/8,500)

0.04

1.00

Prior myocardial infarction

35.3 (24/68)

28.6 (4/14)

25.1 (2,136/8,500)

0.12

0.13

Prior coronary artery bypass grafting

27.9 (19/68)

21.4 (3/14)

17.0 (1,446/8,500)

0.03

0.72

Prior percutaneous coronary intervention

48.5 (33/68)

50.0 (7/14)

42.8 (3,638/8,500)

0.35

0.58

Arterial hypertension

88.2 (60/68)

85.7 (12/14)

79.5 (6,761/8,500)

0.09

0.13

Chronic kidney disease‡

22.7 (15/68)

42.9 (6/14)

16.3 (1,381/8,461)

0.16

0.02

Hyperlipidemia

83.8 (57/68)

92.9 (13/14)

74.2 (6,310/8,500)

0.09

0.12

Cigarette smoking

60.3 (41/68)

35.7 (5/14)

56.3 (4,783/8,500)

0.47

0.12

Current smoker

19.1 (13/68)

0.0 (0/14)

22.7 (1,927/8,500)

0.56

0.05

Previous smoker

41.2 (28/68)

35.7 (5/14)

33.6 (2,856/8,500)

0.21

1.00

Clinical presentation
Asymptomatic coronary artery disease

8.8 (6/68)

7.1 (1/14)

12.4 (1,057/8,500)

0.41

1.00

Stable angina

69.1 (47/68)

78.6 (11/14)

71.2 (6,050/8,500)

0.03

0.77

Unstable angina

17.6 (12/68)

21.4 (3/14)

27.7 (2,355/8,500)

0.05

0.77

Non-STEMI

16.2 (11/68)

21.4 (3/14)

14.5 (1,235/8,500)

0.62

0.44

STEMI

11.8 (8/68)

7.1 (1/14)

9.5 (805/8,500)

0.46

1.00

NYHA functional class II–IV

64.7 (44/68)

78.6 (11/14)

67.5 (5,741/8,500)

0.50

0.57

Ejection fraction, %

55.53  12.80

54.30  5.31

54.88  12.42

0.76

0.73
0.34

Laboratory data
Hemoglobin, g/dl

13.5  1.5

13.6  1.8

14.0  1.5

0.004

Hematocrit, %

39.7  4.4

40.1  5.1

41.0  4.3

0.02

0.45

White blood cells, 1,000/ml

8.28  2.42

7.54  2.65

7.95  3.20

0.32

0.63

Platelet count, 1,000/mm3

225.1  73.2

196.6  52.2

226.8  63.0

0.80

0.07

Values are mean  SD or % (n/N). *Hemorrhagic stroke versus no stroke. †creatinine clearance <60 ml/min calculated by Cockcroft-Gault formula. ‡ischemic stroke versus no stroke.
HS ¼ hemorrhagic stroke; IS ischemic stroke; NYHA ¼ New York Heart Association; STEMI ¼ ST-segment elevation myocardial infarction.
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F I G U R E 2 VerifyNow-Assessed PRU and ARU According to the Type of Stroke at 2 Years

institutional review board at each participating center
approved the study, and all eligible patients signed
written informed consent before enrollment.
The present post hoc analysis from the ADAPT-DES
study has the following objectives: 1) to investigate
the association between P2Y 12 reaction units (PRU)
and aspirin reaction units (ARU) and risk of IS after
successful DES-PCI; 2) to assess the association between PRU and ARU and IS adjusting by CHA2DS 2VASc score, which is an established risk prediction
tool for stroke; and 3) to estimate the adjusted impact
of IS on mortality in a successful DES-PCI population.
The incidence and univariate correlates of hemorrhagic stroke (HS) were also investigated.
STUDY DEFINITIONS. IS was deﬁned according to

guidelines criteria as an episode of neurological
dysfunction caused by focal cerebral, spinal, or
retinal infarction (the latter deﬁned as a brain, spinal
cord, or retinal cell death attributable to ischemia
based on clinical [$24 h], imaging, or pathological
evidence). HS was deﬁned as a rapidly developing
clinical signs of neurological dysfunction attributable
to a focal collection of blood within the brain parenchyma or ventricular system. All stroke events were
site-reported events not adjudicated by a clinical
events

committee

blinded

to

platelet

function

testing. Sites were asked to determine stroke on the
basis of guideline-recommended clinical criteria with
imaging and local neurologist conﬁrmation.
STATISTICAL ANALYSIS. Descriptive statistics are

presented as mean  SD and were compared with the
Student’s t-test; categorical variables are reported as
percentages and were tested with the chi-square test.
Incidence of IS and HS were estimated with the
Kaplan-Meier method. Adjusted hazard ratio (HR) to
evaluate the association between PRU, ARU, and IS
was obtained with multivariable Cox regression
modeling including the following covariates: age, sex,
congestive heart failure, diabetes, hypertension, peripheral arterial disease, smoking, anemia, renal
insufﬁciency, and warfarin pre-PCI.
The study population was categorized according to
the CHA2DS 2-VASc score in 3 categories: low risk
(score ¼ 1), intermediate risk (score ¼ 2 or 3), and high
(score

$4).

The

CHA2 DS2-VASc

score

was

P2Y12 reaction units (PRU) (A) and aspirin reaction units (ARU) (B) in patients with

risk

ischemic, hemorrhagic, and any stroke at 2-year follow-up. IQR ¼ interquartile range.

calculated as reported previously, with the exception
that “history of prior stroke” was empirically set to
zero, because this variable was lacking at the time

and 2 years. An independent clinical events committee

of study enrollment based upon the ADAPT-DES

blinded to platelet function testing results adjudicated

case report form. All patients in the dataset were

all death, myocardial infarction, and stent thrombosis

given a score of 1 by default, given that all of them had

events

coronary artery disease. The predictive value of the

using

original

source

documents.

The
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CHA2 DS2-VASc score (tested as a linear scale) was
assessed in Cox regression models, with receiver-

F I G U R E 3 Kaplan-Meier Estimates of IS and HS at 2 Years Across Levels of P2Y 12

Receptor Inhibition

operating characteristics, area under the curve, and
C-statistic to assess discrimination, and with the
Hosmer-Lemeshow statistic to evaluate calibration.
The impact of IS on all-cause mortality was evaluated by including IS as a time-dependent covariate in
a multivariable Cox regression model together with
the following covariates: age, sex, history of congestive heart failure, diabetes mellitus, hypertension,
peripheral vascular disease, PRU, and ARU. Due to the
rarity of the events, only univariate associations between clinical variables and HS, and HS and all-cause
mortality, are provided. Statistical analyses were
performed with SAS version 9.4 (SAS Institute, Cary,
North Carolina). A 2-sided p < 0.05 was deemed statistically signiﬁcant.

RESULTS
PLATELET

REACTIVITY

AND

RISK

OF

STROKE.

Among 8,582 patients enrolled in the ADAPT-DES

Results are reported across quintiles of P2Y12 reaction units, from the lowest quintile

study, the median follow-up time was 729 (inter-

(more P2Y12 receptor inhibition) to the highest quintile (less P2Y12 receptor inhibition).

quartile range: 703 to 742) days: of these, 316 died (at

HS ¼ hemorrhagic stroke; IS ¼ ischemic stroke; PRU ¼ P2Y12 reaction units.

a median time to death of 352 [interquartile range: 183
to 502] days). Two years of follow-up was completed
in 7,649 patients; among the remainders, 159 patients

receptor inhibitor and DAPT use through 2 years be-

were lost at follow-up, 10 refused 2-year follow-up,

tween patients with versus without IS.

28

patients

withdrew

consent,

whereas

736

Kaplan-Meier estimates of IS and HS across the

had <700 days of follow-up. At 2 years of follow-up,

quintiles of PRU are illustrated in Figure 3. A greater

stroke occurred in 82 patients (1.0%) (Figure 1); an

risk of IS was observed as patients transitioned from

incidence roughly comparable to that of deﬁnite or

the ﬁrst quintile of PRU (more P2Y 12 inhibition) to-

probable ST (1.1% at 2 years). Of these, 68 (0.8%)

ward the ﬁfth quintile of PRU (less P2Y12 inhibition);

(Figure 1) had an IS, and 14 (0.2%) (Figure 1) had an HS.

conversely no signiﬁcant differences were observed

The overall rate of 2-year IS was comparable to that of

in the rates of HS across quintiles. Patients with PRU

deﬁnite or probable ST at 2 years (1.1%). Baseline

>208 had higher risk of IS at 2 years (Figure 4A) (1.2%

clinical and procedural characteristics of patients

vs. 0.5%; univariate HR: 2.18; 95% conﬁdence interval

with IS, HS, and no stroke are reported in Table 1 and

[CI]: 1.32 to 3.60; p ¼ 0.01); an association that per-

Online Table 1. Compared with patients without IS,

sisted following multivariable adjustment (Figure 5)

those who had an IS were older and more commonly

(adjusted HR: 1.84; 95% CI: 1.11 to 3.06; p ¼ 0.02).

female, with a higher prevalence of diabetes and

Conversely, there were no differences in HS in pa-

other cardiovascular comorbidities. Patients with

tients with versus without PRU >208 (Figure 4B)

IS had higher levels of PRU as assessed with the

(0.2% vs. 0.2%; univariate HR: 1.06; 95% CI: 0.39 to

VerifyNow assay (Figure 2A). By contrast, there were

2.84; p ¼ 0.91). Independent correlates of IS are

no differences in PRU between patients with versus

illustrated in Table 2. In addition to PRU, peripheral

without HS. ARU was similar among patients with

artery disease emerged as the strongest correlate of IS

and without stroke (Figure 2B). Medication use

(adjusted HR: 2.44; 95% CI: 1.37 to 4.34; p ¼ 0.003).

through 2 years is reported in Online Table 2.

ARU

Although there were no signiﬁcant differences in

increased risk of IS when modeled as a continuous

prescription of warfarin at discharge, at 2 years,

metric or when a cutoff at ARU >550 was used to

patients who had an IS were more likely to be on

classify patients as aspirin resistant (Figure 5).

was

not

independently

associated

with

warfarin compared with patients who did not have an

Crude rates of IS were highest among patients that

IS. There were no signiﬁcant differences in P2Y 12

had high ARU as well as high PRU (Online Figure 1),
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F I G U R E 4 Kaplan-Meier Curves for IS and HS in Patients With Versus Without PRU

>208

associated with 2-year all-cause mortality (adjusted
HR: 4.16; 95% CI: 1.95 to 8.87; p < 0.0001) and
cardiovascular mortality (adjusted HR: 4.57, 95% CI:
1.86 to 11.24; p ¼ 0.0009).
CHA 2 DS 2 -VASc SCORE, PLATELET REACTIVITY, AND
RISK OF STROKE. Distribution and the predicted risk

for 2-year IS across CHA2DS 2-VASc score categories
in the ADAPT-DES population is illustrated in
Online Figure 3. IS rates across the low-risk, intermediate-risk, and high-risk groups are illustrated in
Figure 6A. The area under the curve for the CHA2DS 2VASc score was of 0.64 (95% CI: 0.58 to 0.70) with
good

calibration,

as

assessed

by

the

Hosmer-

Lemeshow test (p ¼ 0.55). Harrel’s C-statistic for a
model containing CHA2DS 2-VASc was modest (0.65).
Two-year rates of IS per high PRU (PRU >208) and
CHA 2DS2-VASc score >2 are illustrated in Figure 6B.
After adjustment for the CHA2DS 2-VASc score, PRU,
but not ARU, was independently associated with IS
(adjusted HR: 1.18 per 50-PRU increase, 95% CI: 1.03
to 1.34; p ¼ 0.016 vs. adjusted HR: 1.24 per 100-ARU
increase, 95% CI: 0.82 to 1.88; p ¼ 0.30). There was
no evidence of interaction between CHA2DS2-VASc
score and high PRU (p interaction ¼ 0.30).

DISCUSSION
The main ﬁndings of this largescale study investigating the association between on-clopidogrel and
aspirin platelet reactivity and risk for stroke after
successful DES-PCI in more than 8,000 patients are as
follows: 1) After successful DES-PCI, the 2-year incidence of IS was comparable to that of ST; 2) PRU is
independently associated with risk of IS at 2 years,
which was consistent after adjusting for baseline
stroke risk; of note, the observed risk of IS was proKaplan-Meier curves for ischemic stroke (A) and hemorrhagic stroke (B). CI ¼ conﬁdence
interval; other abbreviations as in Figures 1 and 2.

gressively greater across the spectrum of residual
P2Y12 receptor inhibition with the lowest risk in patients in the lowest quintile of PRU (more P2Y12 receptor inhibition) and the greatest risk in those in the

but there was no statistical interaction between

highest quintile of PRU (less P2Y 12 receptor inhibi-

greater PRU and greater ARU (pinteraction ¼ 0.19).

tion); and 3) ARU was not associated with increased

There was also no interaction between greater PRU

risk of IS or HS.

and peripheral artery disease (Online Figure 2)

Atherosclerosis affects the coronary, cerebral, and

(p interaction ¼ 0.45). The effect of greater PRU was also

systemic vasculature in a continuum (10). Athero-

uniform between patients discharged with (per 50-U

thrombosis, which can be deﬁned as an atheroscle-

increase, adjusted HR: 1.15; 95% CI: 0.63 to 1.20) or

rotic lesion disruption with superimposed thrombus

without (adjusted HR: 1.15; 95% CI: 1.00 to 1.32) oral

formation, is a major cause of acute coronary syn-

anticoagulation (p interaction ¼ 0.99).

dromes, cardiac death, and stroke (9). Stroke is the

ASSOCIATION BETWEEN STROKE AND MORTALITY. By

top 5 causes of death in the United States (11).

modeling IS as a time-dependent covariate and by

Because stroke often causes irreversible sequelae,

adjusting for baseline confounders, IS was strongly

early recognition of patients at risk and application of

leading cause of long-term disability and among the
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appropriate preventive measures remain at the
cornerstone of patient care (11). Approximately 90%

F I G U R E 5 Unadjusted and Adjusted Association Between High Platelet Reactivity on

Clopidogrel and on Aspirin With the Risk of IS at 2 Years

of strokes are IS, and most of these are related to
atherothrombosis and/or cardioembolism (12–15). In
the current post hoc analysis from the largescale
ADAPT-DES study, we investigated the incidence,
correlates, and impact of IS in a patient population
with coronary artery disease that was treated with
successful DES-PCI and antiplatelet therapies. The
ADAPT-DES study was designed to investigate the
association between PRU and the 1-year risk of DES
thrombosis, an event considered to be particularly
important to prevent after PCI (6). Interestingly, our
study shows that the observed rates of IS (0.8% at 2
years) were roughly comparable to that of deﬁnite or
probable ST (1.1% at 2 years). Furthermore, the
strength of the association was comparable for PRU
and IS as it was for PRU and ST, with similar

Abbreviations as in Figures 2 and 3.

discrimination (6). Because the effect on morbidity
and mortality of IS is at least of comparable magnitude to that of ST, our ﬁndings imply that the risk of
IS should be taken into consideration when risk-

substudy of the SOCRATES (Acute Stroke or Tran-

stratifying patients and selecting antiplatelet regi-

sient Ischaemic Attack Treated With Aspirin or

mens after PCI.

Ticagrelor and Patient Outcomes) trial, P2Y12 inhibi-

Less P2Y 12 receptor inhibition was associated with

tion with the more potent agent ticagrelor versus

greater risk of IS in both unadjusted and adjusted

COX inhibition with aspirin signiﬁcantly reduced the

analyses. Conversely, in contrast to PRU, ARU was not

risk of ischemic stroke by 27% in the subset of pa-

signiﬁcantly associated with IS risk, although a trend

tients with acute IS or transient ischemic attack of

toward greater risk for IS with increasing ARU was

atherosclerotic origin (17). In terms of DAPT, in the

observed. Although we did not observe a multiplica-

randomized,

tive interaction between PRU and ARU on the risk of

CHANCE (Clopidogrel in High-Risk Patients With

IS, patients with high PRU in combination with high

Acute Non-Disabling Cerebrovascular Events) trial,

ARU had incrementally higher risk of IS (Online

the combination of aspirin and clopidogrel for 21

Figure 1) (þ1.4% on an absolute scale and 3.9-fold

days was superior to aspirin alone in reducing the

on a relative scale compared with patients with

risk for stroke at 90 days after the onset of minor IS

none of these conditions). When interpreted in the

or high-risk transient ischemic attack (18). In addi-

context of available data, our study suggests that

tion, compared with aspirin alone, more intense

double-blinded,

placebo-controlled

ensuring adequate platelet inhibition through the
P2Y12 receptor and the COX pathways can reduce the
risk of IS after PCI. Thus, because the incidence of IS

T A B L E 2 Independent Correlates of Stroke at 2 Years

after PCI appears to be similar to that of deﬁnite or
probable ST, and because IS may have a greater
impact on morbidity and mortality than that of an ST

Adjusted HR
(95% CI)

p Value

Any stroke

event, further attention should be payed to miti-

Peripheral artery disease

2.07 (1.20–3.58)

0.009

gating IS risk.

Sex, female

1.79 (1.12–2.86)

0.01

Aspirin reaction units, per 100-U increase

1.39 (0.97–1.98)

0.07

2.44 (1.37–4.34)

0.003

Our results must be put into perspective with
previous trials investigating the association between antiplatelet therapy and risk for stroke.
Compared with placebo, aspirin therapy demon-

Ischemic stroke
Peripheral artery disease
P2Y12 reaction units, per 50-U increase

1.15 (1.01–1.31)

0.04

Sex, female

1.61 (0.95–2.71)

0.07

strated a reduction in the risk of IS by z15% in
primary prevention trials and z25% in secondary
prevention trials in patients at high risk for cardiovascular

events

1283
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(16).

However,

in

a

Candidate covariates included: age, sex, P2Y12 reaction units >208, diabetes mellitus, peripheral
artery disease, congestive heart failure, and arterial hypertension.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.

recent
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F I G U R E 6 Kaplan-Meier Curves for IS According to the CHA 2 DS 2 -VASc Score and PRU

in

absence

of

signiﬁcant

ischemic

beneﬁt,

as

observed in the SPS3 (Secondary Prevention of Small
Subcortical Strokes) and the MATCH (Management of
Atherothrombosis

with

Clopidogrel

in

High-risk

patients) trials, respectively (19,20).
Because the role of measurement of pharmacological responsiveness to guide antiplatelet therapies in clinical practice remains controversial (21),
we evaluated the association between PRU and ARU
(which remain valid surrogates of the degree of
platelet inhibition) with risk for IS after adjustment
for established clinical risk factors of IS. First, we
observed that the CHA 2DS2-VASc score, which was
developed to guide anticoagulation therapy in patients with atrial ﬁbrillation (22), predicted IS in the
ADAPT-DES population with a C-statistic surprisingly comparable to that observed in cohorts of
patients with atrial ﬁbrillation (23). Of interest, the
association between PRU and risk for IS persisted
after adjustment with the CHA 2DS 2-VASc score,
further reinforcing that ensuring adequate platelet
inhibition may be of value even in the context of
established clinical risk factors for IS.
Current guidelines recommend at least 6 months
and at least 12 months of DAPT therapy after PCI with
DES in patients with stable coronary artery disease
and acute coronary syndromes, respectively (24).
After this guideline-recommended mandatory period,
extension of DAPT may be considered if the riskbeneﬁt ratio of prolonging versus stopping DAPT is
deemed to be favorable. Our study suggests that the
individual risk of IS should be taken into account at
the time of clinical decision making for secondary
prevention with antiplatelet therapies.
STUDY LIMITATIONS. First, because this is a post

hoc analysis from a prospective cohort study, our
results have to be considered hypothesis-generating.
Kaplan-Meier curves for ischemic stroke according to CHA2DS2-VASc score categories (A)

Second, most of the patients in the ADAPT-DES

and Kaplan-Meier curves for ischemic stroke according to CHA2DS2-VASc score cate-

study received clopidogrel as the P2Y12 receptor in-

gories and P2Y12 reaction units (B). Abbreviations as in Figures 2 and 3.

hibitor; therefore, generalizability to novel highpotency antiplatelet drugs remains limited. Third,
history of prior stroke was not captured in the

platelet inhibition by combining aspirin with a P2Y 12

dataset, and therefore, it could not be computed in

receptor inhibitor or thrombin receptor antagonists

the calculation of CHA 2DS2-VASc score for individual

demonstrated a reduction in the risk of both

patients. Fourth, history of atrial ﬁbrillation or

ischemic and all-cause stroke in a population at high

ﬂutter was not captured; however, the effect of PRU

risk for atherothrombosis (34% and 28% relative risk

on risk of IS was similar in patients discharged with

reduction, respectively) (12). However, it should also

or without oral anticoagulation, for which atrial

be noted that in patients with history of lacunar

ﬁbrillation is the most common indication in this

infarcts, the combination of aspirin plus clopidogrel

patient population. Fifth, in the ADAPT-DES study,

versus aspirin alone and the combination of clopi-

stroke was a site-reported event with no blinded

dogrel plus aspirin versus clopidogrel alone were

clinical event committee adjudication. Details on

both associated with increased risk of major bleeding

type of IS (atherothrombotic vs. cardioembolic),
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infarct location, and neurological sequelae were also
not captured. Finally, due to the low number of
events, we were unable to assess the independent
association between PRU and ARU with HS.

PERSPECTIVES
WHAT IS KNOWN? Patients with coronary artery disease are at
an increased risk of IS due to atherothrombosis within the extraor intracranial arterial vasculature or due to cardiac embolism.

CONCLUSIONS

Dual antiplatelet therapy, with aspirin and clopidogrel, reduces

In an all-comers population treated with successful

the risk of stent-related thrombotic events after PCI. Whether

DES-PCI and DAPT, the risk for IS was similar to that

platelet reactivity on clopidogrel inﬂuences the risk for IS re-

of ST and was strongly associated with 2-year mor-

mains unclear.

tality. High on-clopidogrel platelet reactivity was
independently associated with increased risk for IS at
2 years. The magnitude of increase in risk of IS was
greater per lesser degrees of P2Y12 receptor inhibition.
The results of the present investigation suggest that
ensuring optimal platelet inhibition may reduce the

WHAT IS NEW? In patients with coronary artery disease
treated with PCI and dual antiplatelet therapy, high onclopidogrel platelet reactivity is associated with increased risk of
IS. Of note, the observed risk of IS was progressively greater
across the spectrum of residual platelet inhibition, from the
lowest (more platelet inhibition) to the highest (less platelet

risk for IS in this patient population.

inhibition) quintiles of P2Y12 reaction units.
ADDRESS FOR CORRESPONDENCE: Dr. Gregg W.

Stone, Columbia University Medical Center, Cardiovascular Research Foundation, 161 Ft. Washington
Avenue, Herbert Irving Pavilion, 6th Floor, New York,

WHAT IS NEXT? Further research is warranted to understand
whether or not optimal platelet inhibition reduces the risk for IS
in patients with atherosclerotic cardiovascular disease.

New York 10032. E-mail: gstone@crf.org.
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